Screening and application of diagnostic molecular markers and therapeutic targets for ocular fundus neovascularization diseases

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100046117

Enrollment

Unknown

Registered

2021-05-04

Start date

2021-05-07

Completion date

Unknown

Last updated

2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascularization of the fundus disease

Interventions

case group:none

control group:none

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Neovascularization of fundus oculi (diabetic retinopathy;Age-related macular degeneration;Choroidal neovascularization;Patients with retinal vein occlusion secondary neovascularization, etc.) as the case group, and patients with idiopathic macular hole, idiopathic anterior macular membrane, and age-related cataract as the control group, with stable vital signs, and able to complete various treatments and follow-up. 1.Patients who have signed informed consent and are willing to complete treatment and examination; 2.Aged 18 or older, regardless of gender.

Exclusion criteria

Exclusion criteria: Active periocular or ocular inflammation (e.g. blepharitis, conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis).

Design outcomes

Primary

Measure	Time frame
vision;intraocular pressure;ocular fundus;optical coherence tomography, OCT;blood glucose;blood lipid;glycosylated hemoglobin;	—

Countries

China

Contacts

Public ContactDing Chun

The Second Xiangya Hospital of Central South University

chunding@csu.edu.cn+86 18670792378

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026